
|Articles|October 6, 2015
Rayner's Recently Acquired Ophteis OVD Range and What This Means for Cataract Surgery
Professor Steve Arshinoff and Rayner CEO Tim Clover announce Rayner's recent acquisition of the Ophteis OVD range at the Company's celebratory event, held at the 2015 ESCRS in Barcelona.
Advertisement
Redirect to video article
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
PolyActiva and RareSight partner to develop treatments for rare pediatric retinal diseases
2
What ‘I’m Fine’ Really Means: An Open Letter from a Thyroid Eye Disease (TED) Patient
3
Opus Genetics has Type B RMAT meeting with FDA for its gene therapy candidate, OPGx-LCA5
4
AAO 2025: A study of retinal vasculitis events with intravitreal agents
5


















































.png)


